https://doi.org/10.31288/oftalmolzh201555867

Immune Mechanisms, Clinical Features and Course of Non-infectious Uveitis

M.V. Sydorova,1 Cand. Sc. (Med), V.Ie. Kondratiuk,2  Dr. Sc. (Med), Prof., N.G. Bychkova,2  Dr. Sc. (Med), Prof.

1 LLC Medical Center Dobrobut-Poliklinika, 2 Bogomolets National Medical University, Kyiv, Ukraine

Е-mail: mariasydorova@gmail.com

In most countries, the uveitides are responsible for 5-13% of all cases of blindness. Non-infectious uveitides are divided into those with and without known systemic association (both in children and adults). The Standardization of Uveitis Nomenclature (SUN) Working Group used anatomic location of the inflammation as an ontologic dimension, defined the criteria for the activity of inflammatory process, divided uveitis into groups and subgroups based on its course, and defined the tactical treatment algorithm. The uveitis development is based mainly on the alterations in the mechanisms of immunotolerance toward self ocular antigens, and on the emergence of autoagression toward these antigens. An alteration in immune tolerance to ocular antigens occurs if (1) regulatory CD25 + T cell subset is insufficient, and (2) B cells are activated with production of specific antibodies to the uveal tract structures. Systemic therapeutical agents for uveitis include corticosteroids, nonsteroidal anti-inflammatory drugs, cytostatics and immunobiologic agents. There are, however, no clinical guidelines involving the uveitis treatment approaches listed. The analysis of correlations between the degree of the alterations in the immune system and the course of uveitis will allow the development of the algorithm for the treatment of uveal inflammation entities.

Keywords: uveitis, rheumatic diseases, the immune system, clinic, treatment

References

1. Senchenko NL, Schuko AG, Malyshev VV. [Uveitides]. GEOTAR-Media, Moscow; 2010. 156 p. Russian.

2. Maya JR, Hanout M, May P et al. Treatment of Noninfectious Uveitis: Current Options and Agents in Development. Retinal Physician. 2013;(10):20-23.

3. Nussenblatt RB, Whitcup SM. Uveitis: fundamentals and clinical practice. 3rd ed. St.Louis: Mosby; 2010. 480 p.

4. Drozdova EA. [Rheumatic disease-associated uveitis: clinical features, diagnostics, immunopathogenesis and treatment] [Dr. Sc. thesis]. Cheliabinsk (Russia): Urals State Medical Academy; 2006. 319 p. Russian.

5. Ali A, Samson CM. Seronegative spondyloarthropathies and the eye. Curr Opin Ophthalmol. 2007;18(6):476–80.
Crossref

6. Lee RW, Dick AD. Current concepts and future directions in the pathogenesis and treatment of non-infectious intraocular inflammation. Eye (Lond). 2012 Jan;26(1):17-28.
Crossref

7. Zbitneva SV. [Incidence of ocular and ocular adnexal disorders in Ukraine]. Ukr Soc Hyg & Pub Health Org Report.  2010;(3):14-8. Ukrainian.

8. Zhaboiedov GD, Ivanova NV, Kopaienko. [Endogenous anterior uveitis and HLA-B27 antigen]. Oftalmol Zh. 2010;(3):61-6. Russian.
Crossref

9. Nussenblatt RB, Gery I, Weiner HL. et al. Treatment of uveitis by oral administration of retinal antigens: results of a phase I/II randomized masked trial. Am J Ophthalmol. 1997 May;123(5):583-92.

10. Rosenberg K, Feuer W, Davis J. Ocular complication of uveitis. Ophthalmology. 2004 Dec;111(12):2299-306.

11. Ke Y, Jiang G, Sun D. et al. Ocular regulatory T cells distinguish monophasic from recurrent autoimmune uveitis. Invest Ophthalmol Vis Sci. 2008 Sep;49(9):3999-4007.

12. Maca SM, Sobala A, Kahraman G et al. HLA-B27 antigen-associated acute anterior uveitis, coping mechanisms and the subjective impression of stress as a trigger: new insights. In: Program and abstracts of the Association for Research in Vision and Ophthalmology (ARVO) 2008 Annual Meeting; 2008 April 27 - May 1, 2008; Fort Lauderdale, Florida. Abstract 795.

13. Jabs D.A., Nussenblatt R.B., Rosenbaum J.T. Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. Am J Ophthalmol. 2005 Sep;140(3):509-16.

14. Deschenes J, Murray PI, Rao NA et al. International Uveitis Study Group (IUSG): clinical classification of uveitis. Ocul Immunol Inflamm. 2008 Jan-Feb; 16(1):1-2.

15. Foster CS, Vitale AT, editors. Diagnosis and treatment of uveitis. 2nd ed. New Dehli: Jaypee-Highlights; 2013. p101–295.

16. Uy HS, Christen WG, Foster CS. HLA-B27-associated uveitis and cystoid macular edema. Ocul Immunol Inflamm. 2001 Sep;9(3):177-83.

17. Huhtinen M. Acute anterior uveitis and HLA-B27: infectious background, systemic inflammation and prognosis of the patients [dissertation]. [Helsinki]: University of Helsinki; 2002. 96 p.

18. Schewitz-Bowers LР, Lee RW J, Dick DA. Immune mechanisms of intraocular inflammation. Expert Rev Ophthalmol. 2010;5(1):43–58.

19. Streilein J.W. Immunological non-responsiveness and acquisition of tolerance in relation to immune privilege in the eye. Eye (Lond). 1995;9 ( Pt 2):236-40.

20. Edelsten C, Reddy MA, Stamford MR, et al. Visual loss associated with uveitis in English primary and referral centers. Am J Ophthalmol. 2003;5:676-80.

21. Aarvak Т, Natvig JB. Cell-cell interactions in synovitis: Antigen presenting cells and T cell interaction in rheumatoid arthritis. Arthritis Res. 2001;3(1):13–7.

22. Wood B. An Overview of Uveitis and Its Management. US Pharmacist. April 1, 2011. Available from www.uspharmacist.com. [Accessed 14 April 2013].

23. Chang JH, McCluskey PJ, Grigg JR. Recurrent hypopyon in chronic anterior uveitis of pauciarticular juvenile idiopathic arthritis. Br J Ophthalmol. 2006; 90(10):1327–8.

24. Godzenko AA. [Perspectives for treatment of rheumatic disease-associated uveitis]. Modern Rheumatol. 2011;(2):37-42. Russian.

25. Cervantes-Castaneda RA, Bhat PV, Huynh N et al. The role of azathioprine in the treatment of ocular inflammatory disease: a six month follow-up analysis. In: Program and abstracts of the Association for Research in Vision and Ophthalmology (ARVO) 2008 Annual Meeting; 2008 April 27 - May 1, 2008; Fort Lauderdale, Florida. Abstract 5822.

26. Forrester JV, Xu H, Kuffova L, Dick AD et al. Dendritic cell physiology and function in the eye. Immunol Rev. 2010;234(1):282–304.

27. Grewal I.S., Flavell R.A. The role of CD40 ligand in costimulation and T-cell activation. Immunol Rev. 1996 Oct;153:85-106.

28. Ruggieri S, Frassanito MA, Dammacco R et al. Treg lymphocytes in autoimmune uveitis. Ocul Immunol Inflamm. 2012 Aug;20(4):255-61.

29. Atan D, Fraser-Bell S, Plskova J et al. Cytokine Polymorphism in Noninfectious Uveitis. Invest Ophthalmol Vis Sci. 2010 Aug;51(8):4133-42.

30. Hecker KH, Niizeki H,  Streilein JW. Distinct roles for transforming growth factor-?2 and tumour necrosis factor-? in immune deviation elicited by hapten-derivatized antigen-presenting cells. Immunology. 1999;96(3):372–80.

31. Chen L, Yang P, Zhou H. et al. Diminished frequency and function of CD4+CD25 high regulatory T cells associated with active uveitis in Vogt-Koyanagi-Harada syndrome. Invest Ophthalmol Vis Sci. 2008 Aug;49(8):3475-82.

32. Matta B, Jha P, Bora PS et al. Tolerance to Melanin-Associated Antigen in Autoimmune Uveitis Is Mediated by CD4+CD25+ T-Regulatory Cells. Am J Pathol. 2008 Nov; 173(5): 1440–1454.

33. Streilein JW, Niederkorn JY. Induction of anterior chamber-associated immune deviation requires an intact, functional spleen. J Exp Med. 1981 May 1; 153(5): 1058–67.

34. Elschnig A. Studien sur sympathischen Ophthalmie: Die Antigene Wirkung der Augenpigmente. Graefes Arch Ophthalmol. 1910;67:509-46.

35. Wacker WB, Barbee JY, Macdonald R. Experimental allergic uveitis III. Manifestations produced in the guinea pig by immunization with homologous retina. Invest Ophthalmol Vis Sci. 1969;8(4):381-91.

36. Rai G, Saxena S, Kumar H et al. Human retinal S-antigen: T cell epitope mapping in posterior uveitis patients. Exp Mol Pathol. 2001 Apr;70(2):140-5.

37. Hankey DJ, Lightman SL, Baker D et al. Interphotoreceptor retinoid binding protein peptide-induced uveitis in B10.RIII mice: characterization of disease parameters and immunomodulation. Exp Eye Res. 2001; 72(3):341-50.

38. Shao H, Lei S, Sun SL et al. Conversion of Monophasic to Recurrent Autoimmune Disease by Autoreactive T Cell Subsets. J Immunol. 2003 Nov 15;171(10):5624-30.

39. Lee RW, Schewitz LP, Nicholson LB et al. Steroid refractory CD4+ T cells in patients with sight-threatening uveitis. Invest Ophthalmol Vis Sci. 2009 Sep;50(9):4273-8.

40. Couch SM, Bakri SJ. Intravitreal triamcinolone for intraocular inflammation and associated macular edema. Clin Ophthalmol. 2009;3:41-7.

41. Lee FF, Foster CS. Pharmacotherapy of uveitis. Expert Opin Pharmacother. 2010 May;11(7):1135-46.

42. Nguyen QD, Hatef E, Kayen B et al. A cross-sectional study of the current treatment patterns in noninfectious uveitis among specialists in the United States. Ophthalmology. 2011 Jan;118(1):184-90.

43. Savko VV, Konovalova NV, Naritcyna NI. [Features of treatment of chronic uveitis].  Oftalmol Zh. 2009;(3):83-6. Russian.

44. Bae J.H., Lee C.S., Lee S.C. Efficacy and safety of intravitreal bevacizumab compared with intravitreal and posterior sub-tenon triamcinolone acetonide for treatment of uveitic cystoid macular edema. Retina. 2011;31(1):111-8.

45. Kempen JH, Daniel E, Gangaputra S et al. Methods for identifying long-term adverse effects of treatment in patients with eye diseases: the Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study. Ophthalmic Epidemiol. 2008 Jan-Feb;15(1):47-55.

46. Galor A, Jabs DA, Leder HA. Comparison of Antimetabolite Drugs as Corticosteroid-Sparing Therapy for Noninfectious Ocular Inflammation. Ophthalmology. 2008 Oct;115(10):1826-32.

47. Nguyen QD, Ibrahim MA, Watters A. Ocular tolerability and efficacy of intravitreal and subconjunctival injections of sirolimus in patients with non-infectious uveitis: primary 6-month results of the SAVE Study. J Ophthalmic Inflamm Infect. 2013 Feb 11;3(1):32.

48. Sobrin L, Christen W, Foster CS. Mycophenolate mofetil after methotrexate failure of intolerance in the treatment of scleritis or uveitis. Ophthalmology. 2008 Aug;115(8):1416-21.

49. Absalikova DK, Mal’khanov VB. [Clinical and laboratory validation of concomitant NSAIDs and antioxidant therapy for endogenous uveitis]. ONU Report. 2011;133(14):12-5. Russian.

50. Lowder C, Belfort R Jr, Lightman S et al. Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol. 2011 May;129(5):545-53.

51. Taylor SR, Banker A, Schlaen A et al. Intraocular methotrexate can induce extended remission in some patients in noninfectious uveitis. Retina. 2013 Nov-Dec;33(10):2149-54.

52. Okada AA. The dream of biologics in uveitis. Arch Ophthalmol. 2010 May;128(5):632-5.

53. Smith JR, Levinson RD, Holland GN et al. Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. Arthritis Rheum. 2001 Jun;45(3):252-7.

54. Imrie FR, Dick AD. Biologics in the treatment of uveitis. Curr Opin Ophthalmol. 2007 Nov;18(6):481-6.

55. Tomkins-Netzer O, Taylor SR, Lightman S. Can Rituximab Induce Long-Term Disease Remission in Patients with Intra-Ocular Non-Infectious Inflammation? Ophthalmologica. 2013;230(3):109-15.